肾移植后快速撤减激素的5年观察性随访:疗效与安全性良好
Harmony试验的5年观察性随访纳入同意参与的肾移植受者,评估快速撤减激素(RSWD)的长期疗效与安全性。随访显示活检证实的急性排斥和死亡删失的移植物丢失率仍低且与RSWD无关,RSWD是患者生存的独立有利因素(校正HR 0.554,95%CI 0.314-0.976;
要点
- 5年随访中活检证实的急性排斥和死亡删失的移植物丢失率仍低,且与快速撤减激素无关。
- 原1年研究期内快速撤减激素组移植后糖尿病发病减少,随访期新发病例未抵消该获益。
核心结论
- Harmony随访数据在现代免疫抑制治疗下确认,快速撤减激素在免疫学低风险的老年白种肾移植受者中5年内疗效良好且安全性有益。
研究设计与样本
- 随机对照Harmony试验(587例以尸体供肾为主的肾移植受者)的5年观察性随访研究,仅纳入同意参与者,收集第2年起临床事件。
主要发现
- 活检证实的急性排斥和死亡删失的移植物丢失率仍低,且与快速撤减激素无关。
- 原1年研究期内快速撤减激素组移植后糖尿病发病减少,随访期新发病例未抵消该获益。
- 随访期内机会性感染、恶性肿瘤、心血管疾病/危险因素、供者特异性抗体形成或肾功能等发生率无差异。
临床怎么用
- 在免疫学低风险的老年肾移植受者中,快速撤减激素在现代免疫抑制方案下5年随访显示疗效良好且安全性有益。
局限性
- 原文述及该研究为试验后随访研究,具有此类研究的所有局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported excellent efficacy and improved safety aspects of rapid steroid withdrawal (RSWD) in the randomized controlled 1-year "Harmony" trial with 587 predominantly deceased-donor kidney transplant recipients randomized either to basiliximab or rabbit antithymocyte globulin induction therapy and compared with standard immunosuppressive therapy consisting of basiliximab, low tacrolimus once daily, mycophenolate mofetil and corticosteroids. METHODS: The 5-year post-trial follow-up (FU) data were obtained in an observational manner at a 3- and a 5-year visit only for those Harmony patients who consented to participate and covered clinical events that occurred from the second year onwards. RESULTS: Biopsy-proven acute rejection and death-censored graft loss rates remained low and independent of RSWD. Rapid steroid withdrawal was an independent positive factor for patient survival (adjusted hazard ratio 0.554, 95% confidence interval 0.314-0.976; P = .041).The reduced incidence of post-transplantation diabetes mellitus in RSWD patients during the original 1-year study period was not compensated by later incidences during FU. Incidences of other important outcome parameters such as opportunistic infections, malignancies, cardiovascular morbidity/risk factors, donor-specific antibody formation or kidney function did not differ during FU period. CONCLUSIONS: With all the limitations of a post-trial FU study, the Harmony FU data confirm excellent efficacy and beneficial safety aspects of RSWD under modern immunosuppressive therapy over the course of 5 years after kidney transplantation in an immunologically low-risk, elderly population of Caucasian kidney transplant recipients. Trial registration: Clinical trial registration number: Investigator Initiated Trial (NCT00724022, FU study DRKS00005786).
引用
- Stumpf J, Thomusch O, Opgenoorth M, et al. Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study). Nephrol Dial Transplant. 2023. PMID: 37391381. doi:10.1093/ndt/gfad130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。